DaraprimMartin ShkrelTuring PharmaceuticalsInterview

New York Times profile

20 Sep, 2015

The New York Times profiles Shrekli, who defends the Daraprim price rise by saying many patients use the drug for far less than a year and that the price is now more in line with those of other drugs for rare diseases.

This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business. This is still one of the smallest pharmaceutical products in the world. It really doesn’t make sense to get any criticism for this.

Add your comments below...

Latest Posts